The activation of asparagine synthetase by the transcription factor FOXM1 plays a pivotal role in the initiation and progression of ESCC

IF 3.2 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Gene Medicine Pub Date : 2024-10-02 DOI:10.1002/jgm.3741

Jing-Jing Lian, Zhao-Xing Li, Hui-ling Lin, Ming-Chuang Sun, Hao Wu, An-Qi Feng, Kang Fang, Xiao-Yuan Wang, Ai-Ping Xu, Yuan Chu, Li Zhang, Tao Chen, Mei-Dong Xu

{"title":"The activation of asparagine synthetase by the transcription factor FOXM1 plays a pivotal role in the initiation and progression of ESCC","authors":"Jing-Jing Lian, Zhao-Xing Li, Hui-ling Lin, Ming-Chuang Sun, Hao Wu, An-Qi Feng, Kang Fang, Xiao-Yuan Wang, Ai-Ping Xu, Yuan Chu, Li Zhang, Tao Chen, Mei-Dong Xu","doi":"10.1002/jgm.3741","DOIUrl":null,"url":null,"abstract":"<p>This study explores the role of the transcription factor FOXM1 in the initiation and progression of oesophageal squamous cell carcinoma (ESCC). Our findings reveal that FOXM1 is highly expressed in ESCC and correlates with the prognosis of the disease. The relationship between FOXM1 and asparagine synthetase (ASNS) is investigated, and the study demonstrates that FOXM1 activates ASNS, impacting the tumour stemness of ESCC. In this study, we reveal the association between FOXM1 and ESCC development, as well as FOXM1’s promotion of migration and proliferation in ESCC cells. The study also highlights FOXM1’s regulation of ASNS transcription and the functional role of ASNS in ESCC metastasis and growth. Furthermore, the study explores the impact of FOXM1 and ASNS on ESCC stemness and their potential implications for chemotherapy resistance.</p>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 10","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgm.3741","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gene Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgm.3741","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study explores the role of the transcription factor FOXM1 in the initiation and progression of oesophageal squamous cell carcinoma (ESCC). Our findings reveal that FOXM1 is highly expressed in ESCC and correlates with the prognosis of the disease. The relationship between FOXM1 and asparagine synthetase (ASNS) is investigated, and the study demonstrates that FOXM1 activates ASNS, impacting the tumour stemness of ESCC. In this study, we reveal the association between FOXM1 and ESCC development, as well as FOXM1’s promotion of migration and proliferation in ESCC cells. The study also highlights FOXM1’s regulation of ASNS transcription and the functional role of ASNS in ESCC metastasis and growth. Furthermore, the study explores the impact of FOXM1 and ASNS on ESCC stemness and their potential implications for chemotherapy resistance.

查看原文本刊更多论文

转录因子 FOXM1 对天冬酰胺合成酶的激活在 ESCC 的发生和发展过程中起着至关重要的作用。

本研究探讨了转录因子FOXM1在食管鳞状细胞癌（ESCC）的发生和发展过程中的作用。我们的研究结果表明，FOXM1在ESCC中高表达，并与疾病的预后相关。研究还探讨了FOXM1与天冬酰胺合成酶（ASNS）之间的关系，结果表明FOXM1能激活ASNS，从而影响ESCC的肿瘤干性。在这项研究中，我们揭示了 FOXM1 与 ESCC 发展之间的联系，以及 FOXM1 对 ESCC 细胞迁移和增殖的促进作用。研究还强调了 FOXM1 对 ASNS 转录的调控以及 ASNS 在 ESCC 转移和生长中的功能作用。此外，研究还探讨了FOXM1和ASNS对ESCC干性的影响及其对化疗耐药性的潜在影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gene Medicine 医学-生物工程与应用微生物

CiteScore

6.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The aims and scope of The Journal of Gene Medicine include cutting-edge science of gene transfer and its applications in gene and cell therapy, genome editing with precision nucleases, epigenetic modifications of host genome by small molecules, siRNA, microRNA and other noncoding RNAs as therapeutic gene-modulating agents or targets, biomarkers for precision medicine, and gene-based prognostic/diagnostic studies. Key areas of interest are the design of novel synthetic and viral vectors, novel therapeutic nucleic acids such as mRNA, modified microRNAs and siRNAs, antagomirs, aptamers, antisense and exon-skipping agents, refined genome editing tools using nucleic acid /protein combinations, physically or biologically targeted delivery and gene modulation, ex vivo or in vivo pharmacological studies including animal models, and human clinical trials. Papers presenting research into the mechanisms underlying transfer and action of gene medicines, the application of the new technologies for stem cell modification or nucleic acid based vaccines, the identification of new genetic or epigenetic variations as biomarkers to direct precision medicine, and the preclinical/clinical development of gene/expression signatures indicative of diagnosis or predictive of prognosis are also encouraged.